Association between methotrexate-induced Stevens-Johnson syndrome/toxic epidermal necrolysis and furosemide: a real-world disproportionality analysis

References

• Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med. 2011 Jun;39(6):1521–1532.
   PubMed Web of Science ®Google Scholar
• Downey A, Jackson C, Harun N, et al. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012 Jun;66(6):995–1003.
   PubMed Web of Science ®Google Scholar
• Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013 Aug;69(2):173.e1.
   Web of Science ®Google Scholar
• Heymann WR. SkinSerious: disseminated intravascular coagulation complicating Stevens- Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2021 Mar;84(4):911–912.
   PubMed Web of Science ®Google Scholar
• Charlton OA, Harris V, Phan K, et al. Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review. Adv Wound Care (New Rochelle). 2020 Jul;9(7):426–439.
   PubMed Web of Science ®Google Scholar
• Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015 Dec;16(6):475–493.
   PubMed Web of Science ®Google Scholar
• Gervasini G, Mota-Zamorano S. Clinical implications of methotrexate pharmacogenetics in childhood acute lymphoblastic leukaemia. Curr Drug Metab. 2019 Jan;20(4):313–330.
   PubMed Web of Science ®Google Scholar
• Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016 Apr;353:i177R7.
   Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277–2294.
   PubMed Web of Science ®Google Scholar
• Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018 Jan;57(1):e1–e45.
   PubMed Web of Science ®Google Scholar
• Katturajan R, V S, Rasool M, et al. Molecular toxicity of methotrexate in rheumatoid arthritis treatment: a novel perspective and therapeutic implications. Toxicology. 2021 Sep;461:152909. DOI:10.1016/j.tox.2021.152909
   PubMed Web of Science ®Google Scholar
• Carone L, Oxberry SG, Twycross R, et al. Furosemide. J Pain Symptom Manage. 2016 Jul;52(1):144–150. DOI:10.1016/j.jpainsymman.2016.05.004
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021 Nov;22(6):1–14.
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002 Jan;11(1):3–10. DOI:10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–436.
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–908. DOI:10.1111/j.1365-2125.2011.04037.x
   PubMed Web of Science ®Google Scholar
• Ye X, Fu Z, Wang H, et al. A computerized system for signal detection in spontaneous reporting system of Shanghai China. Pharmacoepidemiol Drug Saf. 2009;18(2):154–158. DOI:10.1002/pds.1695
   PubMed Web of Science ®Google Scholar
• Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998 Jun;54(4):315–321. DOI:10.1007/s002280050466
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Ueta M. Editorial: the Updated Understanding of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Front Med. 2021 Dec;8:811570.
   Web of Science ®Google Scholar
• East-Innis AD, Thompson DS. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis at the University Hospital of the West Indies, Jamaica. W Indian Med J. 2013 Sep;62(7):589–592.
   PubMed Web of Science ®Google Scholar
• Wolf R, Orion E, Marcos B, et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005 Mar;23(2):171–181.
   PubMed Web of Science ®Google Scholar
• Singh R, Meena M, Patidar A, et al. Toxic Epidermal Necrolysis-Like Lesions as Cutaneous Manifestation of Acute Methotrexate Toxicity. Indian Dermatol Online J. 2021 Mar;12(2):340–341.
   PubMedGoogle Scholar
• Rachana PR, Anuradha HV, Mounika R. Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap Secondary to Interaction Between Methotrexate and Etoricoxib: a Case Report. J Clin Diagn Res. 2015 Jul;9(7):Fd01–03. DOI:10.7860/JCDR/2015/14221.6244
   PubMedGoogle Scholar
• Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010 Dec;5(1):39.
   PubMedGoogle Scholar
• Akinci B, Sivis ZO, Sahin A, et al. Stevens-Johnson Syndrome associated with methotrexate treatment for acute lymphoblastic leukemia: a case report. Arch Argent Pediatr. 2018 Jun;116(3):e459–e462.
   PubMed Web of Science ®Google Scholar
• Primka EJ, Camisa C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol. 1997 May;36(5):815–818.
   PubMed Web of Science ®Google Scholar
• Al-Saffar F, Ibrahim S, Patel P, et al. Skin rash in the intensive care unit: Stevens-Johnson syndrome, toxic epidermal necrolysis, or a rare manifestation of a hidden cutaneous malignancy: a case report. Mol Clin Oncol. 2016 Mar;4(3):413–415.
   PubMedGoogle Scholar
• Kaufman WS, McNamara EK, Curtis AR, et al. Febrile ulceronecrotic Mucha-Habermann disease (pityriasis lichenoides et varioliformis acuta fulminans) presenting as Stevens-Johnson syndrome. Pediatr Dermatol. 2012 Mar;29(2):135–140.
   PubMed Web of Science ®Google Scholar
• Paret N, Baldin B, Jonville-Bera A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome in furosemide-treated patients: a study of the French Pharmacovigilance database. Fundam Clin Pharmacol. 2011 Apr;25:101.
   Web of Science ®Google Scholar
• Mebazaa A, Moula H, Beji S, et al. furosemide-induced toxic epidermal necrolysis. Drug Saf. 2009;32(10):960–961.
   Web of Science ®Google Scholar
• Kennedy AC, Lyell A. Acquired epidermolysis bullosa due to high-dose frusemide. Br Med J. 1976 Jun;1(6024):1509.
   PubMedGoogle Scholar
• Dhande R, Madke B, Singh A, et al. Carvedilol induced toxic epidermal necrolysis: a rare case report. J Clin Diagn Res. 2021 Dec;15(12):Wd1–Wd2.
   Web of Science ®Google Scholar
• Pierard-Franchimont C, Lesuisse M, Humbert P, et al. Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf. 2012 Nov;7(5):357–360.
   PubMedGoogle Scholar
• Hani N, Casper C, Groth W, et al. Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease. Eur J Dermatol. 2000 Oct;10(7):548–550.
   PubMed Web of Science ®Google Scholar
• Yang CH, Yang LJ, Jaing TH, et al. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Int J Dermatol. 2000 Aug;39(8):621–623.
   PubMed Web of Science ®Google Scholar
• King LD, Sia H, Anoopkumar‐dukie S. Trimethoprim‐sulfamethoxazole as Pneumocystis jiroveci pneumonia prevention in patients undergoing methotrexate therapy for hematological malignancies: a review of the literature. Hematol Oncol. 2020 Nov;39(2):170–175.
   Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncology. 2006 Jun;11(6):694–703.
   Google Scholar
• Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol. 2009 Mar;63(4):599–604.
   PubMed Web of Science ®Google Scholar
• Evans WE, Christensen ML. Drug interactions with methotrexate. J Rheumatol Suppl. 1985 Dec;12 Suppl 12:15–20.
   PubMedGoogle Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803.
   PubMed Web of Science ®Google Scholar